David Hung bought $820k of NUVB
PRESIDENT AND CEO at Nuvation Bio Inc.. 500,000 shares at an average of $1.64, traded Apr 4, 2025, filed Apr 8, 2025.
Score components
- +25RoleCEO
- +22Trade size$820k at market
- -5Relative to holdingsUnder 1% of holdings (0.9%)
- +18Price context0% above the 52-week low; 49% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +26.5%, 3m +23.5%, 6m +120.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-010446, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 4, 2025 | POpen-market purchase Class A Common Stock | +200,000 | $1.66 | $333k | 58,481,054 | Apr 8, 2025 |
| Apr 7, 2025 | POpen-market purchase Class A Common Stock | +300,000 | $1.63 | $488k | 58,781,054 | Apr 8, 2025 |
Related signals
Other insiders at Nuvation Bio Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Nuvation Bio Inc. | Gary Hattersley CHIEF SCIENTIFIC OFFICER | $709k 100,000 shares | -100% | |
| 37Weak | Nuvation Bio Inc. | Stacy Markel CHIEF PEOPLE OFFICER | $753k 125,000 shares | -79% | |
| 31Weak | Nuvation Bio Inc. | Kerry Wentworth CHIEF REGULATORY OFFICER | $379k 63,000 shares | -54% | |
| 36Weak | Nuvation Bio Inc. | Philippe Sauvage Chief Financial Officer | $286k 47,668 shares | -79% | |
| 36Weak | NUVBbuy Nuvation Bio Inc. | Robert Mashal director | $118k 25,000 shares | +13% | |
| 21Weak | Nuvation Bio Inc. | Dongfang Liu CHIEF MEDICAL OFFICER | $251k 50,000 shares | -74% | |
| 10Weak | Nuvation Bio Inc. | Kerry Wentworth CHIEF REGULATORY OFFICER | $184k 36,750 shares | -41% | |
| 32Weak | Nuvation Bio Inc. | Kerry Wentworth CHIEF REGULATORY OFFICER | $904k 200,000 shares | -79% | |
| 60Notable | Nuvation Bio Inc. | Dongfang Liu CHIEF MEDICAL OFFICER | $1.2M 150,000 shares | -89% | |
| 46Moderate | Nuvation Bio Inc. | Dongfang Liu CHIEF MEDICAL OFFICER | $155k 20,000 shares | -71% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.